Pro-Dex (NASDAQ:PDEX) Stock Crosses Below Two Hundred Day Moving Average of $17.60

Pro-Dex, Inc. (NASDAQ:PDEX)’s stock price crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $17.60 and traded as low as $17.15. Pro-Dex shares last traded at $17.23, with a volume of 3,131 shares trading hands.

Analyst Upgrades and Downgrades

Separately, StockNews.com downgraded shares of Pro-Dex from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th.

Pro-Dex Price Performance

The company has a quick ratio of 2.16, a current ratio of 3.66 and a debt-to-equity ratio of 0.26. The firm’s 50-day moving average is $18.66 and its 200-day moving average is $17.61. The company has a market cap of $61.11 million, a PE ratio of 23.21 and a beta of 0.60.

Pro-Dex (NASDAQ:PDEX) last announced its quarterly earnings results on Thursday, February 8th. The medical instruments supplier reported $0.14 earnings per share (EPS) for the quarter. The company had revenue of $12.59 million for the quarter. Pro-Dex had a net margin of 5.59% and a return on equity of 8.97%.

Institutional Investors Weigh In On Pro-Dex

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in shares of Pro-Dex by 2.0% during the fourth quarter. Vanguard Group Inc. now owns 123,650 shares of the medical instruments supplier’s stock valued at $2,166,000 after buying an additional 2,454 shares during the last quarter. Punch & Associates Investment Management Inc. grew its holdings in shares of Pro-Dex by 8.1% during the third quarter. Punch & Associates Investment Management Inc. now owns 69,610 shares of the medical instruments supplier’s stock valued at $1,093,000 after buying an additional 5,235 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Pro-Dex by 1.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 58,751 shares of the medical instruments supplier’s stock valued at $920,000 after buying an additional 625 shares during the last quarter. LSV Asset Management grew its holdings in shares of Pro-Dex by 13.9% during the first quarter. LSV Asset Management now owns 35,581 shares of the medical instruments supplier’s stock valued at $588,000 after buying an additional 4,346 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in shares of Pro-Dex by 31.1% during the fourth quarter. Northern Trust Corp now owns 25,900 shares of the medical instruments supplier’s stock valued at $454,000 after buying an additional 6,141 shares during the last quarter. Hedge funds and other institutional investors own 15.28% of the company’s stock.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.